| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA853: Avatrombopag for treating primary chronic immune thrombocytopenia |
|
Medicine details |
|
| Medicine name | avatrombopag (Doptelet®) |
| Formulation | 20 mg film-coated tablet |
| Reference number | 4433 |
| Indication | Treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) |
| Company | Swedish Orphan Biovitrum Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 16/11/2022 |
| NICE guidance | TA853: Avatrombopag for treating primary chronic immune thrombocytopenia |